The effect of TKI therapy and chemotherapy treatment delivery sequence on total progression-free survival in patients with advanced EGFR-mutated NSCLC.
Sign Up to like & getrecommendations! Published in 2020 at "Oncology letters"
DOI: 10.3892/ol.2020.11535
Abstract: The present study aimed to evaluate the total progression-free survival (PFS) time of the 1st-line chemotherapy (CHT)/2nd-line tyrosine kinase inhibitor (TKI) and 1st-line TKI/2nd-line CHT therapeutic regimens. Data from patients with non-small-cell lung cancer (NSCLC)… read more here.
Keywords: 2nd line; line; line cht; line tki ... See more keywords